Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T08:11:34.583Z Has data issue: false hasContentIssue false

Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat?

Published online by Cambridge University Press:  24 April 2024

Rhett Vandervelde
Affiliation:
Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA
Mark E. Mlynarek
Affiliation:
Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA
Mayur Ramesh
Affiliation:
Department of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA
Nimish Patel
Affiliation:
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA
Michael P. Veve
Affiliation:
Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USADepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
Benjamin A. August*
Affiliation:
Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USADepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
*
Corresponding author: Benjamin August; Email: baugust1@hfhs.org

Abstract

Objective:

Data evaluating timeliness of antibiotic therapy in Clostridioides difficile infections (CDI) are not well established. The study’s purpose was to evaluate the impact of time-to-CDI treatment on disease progression.

Methods:

A case–control study was performed among hospitalized patients with CDI from 1/2018 to 2/2022. Inclusion criteria were age ≥65 years, first occurrence, non-severe CDI at symptom onset, and CDI treatment for ≥72 hours. Cases included patients who progressed to severe or fulminant CDI; controls were patients without CDI progression. Time to CDI treatment was evaluated in three ways: a classification and regression tree (CART)-defined threshold, time as a continuous variable, and time as a categorical variable.

Results:

272 patients were included; 136 with CDI progression, 136 patients without. The median (IQR) age was 74 (69–81) years, 167 (61%) were women, and 108 (40%) were immunosuppressed. CDI progression patients more commonly were toxin positive (66 [49%] vs 52 [38%], P = .087) with hospital-acquired disease (57 [42%] vs 29 [21%], P < 0.001). A CART-derived breakpoint for optimal time-to-CDI treatment of 64 hours established early (184, 68%) and delayed treatment (88, 32%). When accounting for confounding variables, delayed CDI treatment was associated with disease progression (adjOR, 4.6; 95%CI, 2.6–8.2); this was observed regardless of how time-to-CDI-active therapy was evaluated (continuous adjOR, 1.02; categorical adjOR, 2.11).

Conclusion:

Delayed CDI treatment was associated with disease progression and could represent an important antimicrobial stewardship measure with future evaluation.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Baseline characteristics of patients age ≥65 years with C. difficile progression from non-severe to severe/fulminant disease and without C. difficile progression

Figure 1

Table 2.Variables associated with C. difficile progression from non-severe to severe or fulminant disease